To visit the old Ventura website, click here.
Ventura Wealth Clients Login here
Refer and earnSupport
logosearch
Create Account
hamburger
home
breadcrumbStocks
breadcrumbAlkem Laboratories Ltd Share Price
breadcrumbResults

Quarterly results

rupeeShow figures in :
rupeeShow figures in :

Quarterly results

Quarter ended on June 30, 2025Data in Crores of INR
Revenue
₹ 3.37K+11.19% from last year
Operating profits
₹ 875.54+20.11% from last year
Net income
₹ 668.32+21.46% from last year

Financial reports

Data is unavailable

INCOME STATEMENTinfo2
Data in Crores of INR

Data is unavailable

BALANCE SHEETinfo2
Data in Crores of INR
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012FY 2011
Net worth11984.8710312.069045.298637.907376.736160.675439.344863.774467.643691.962999.052584.972177.311820.051433.69
Fixed assets2852.312872.782682.852901.732792.982908.012530.442283.591797.041449.541374.341170.011072.12919.17692.73
Debt1062.791213.971307.152580.121700.721615.52944.07997.56659.46657.501305.921128.431548.541004.75909.36
docView detailed balance sheet
arrow
CASH FLOWinfo2
Data in Crores of INR
FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Operating1912.841948.071682.501111.021264.90585.08779.65266.04471.14725.83325.47
Investing -1298.76-1008.50112.84-1435.13-998.54-741.35-316.39-357.23-285.93202.27-236.97
Financing -810.99-1145.01-1760.82379.57-271.7579.15-378.9484.56-137.88-927.27-51.78

Financial ratios

Profitability ratiosinfo2
ROA14.77%
ROE19.93%
ROCE21.56%
EPS181.14%
Net profit margin17.09%
Operating profit margin15.57%
Dividend per share45%
Operational ratiosinfo2
Quick ratio1.99%
Current ratio2.73%
Interest coverage21.76%
Assets turnover1.29%
Debt to equity0.09%
Valuation ratiosinfo2
P/E ratio28.38%
P/B ratio5.14%
Dividend yield0.83%
EV/EBITDA
Alkem Laboratories Limited is among India’s leading global pharmaceutical companies. The company develops, manufactures and markets high-quality pharmaceutical products across all major therapeutic segments. The Company is a leading player in the acute therapeutic segment and a fast-growing player in the chronic therapeutic segment. India operations are underpinned by a robust sales and distribution network and extensive brand building and marketing efforts. The Company’s International business, built on a strong platform of a large and growing product pipeline, is a core part of its growth. These products are distributed through the Company’s own sales and commercial infrastructure.
personal

Grow your wealth with more research recommendations

+91